What is the cost-effectiveness and economic value of PCSK9 inhibitors?
The cost-effectiveness and economic value of PCSK9 inhibitors have been assessed by using simulation models (Online Data Supplements 47 and 48); the published models are based on different sets of assumptions. Compared with statin therapy for secondary prevention, PCSK9 inhibitors have incremental cost-effectiveness ratiosS7.1-3 from $141700 to $450000 per quality-adjusted life-year (QALY) added, at mid-2018 list prices. None of the published models report good value (<$50000 per QALY added; Table 12), and virtually all indicate low value ( $150000 per QALY added).